- Home
- INBK vs TLSA Comparison
INBK vs TLSA Comparison
Compare INBK & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INBK | TLSA |
|---|---|---|
| Founded | 1999 | 2013 |
| Country | United States | United Kingdom |
| Employees | 355 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.3M | 164.1M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | INBK | TLSA |
|---|---|---|
| Price | $23.92 | $1.49 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $23.25 | N/A |
| AVG Volume (30 Days) | 56.1K | ★ 219.8K |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.06% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $279.34 | N/A |
| Revenue Next Year | $12.97 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.05 | $1.14 |
| 52 Week High | $28.51 | $2.60 |
Technical Indicators
Market Signals| Indicator | INBK | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 50.19 | 55.53 |
| Support Level | $23.26 | $1.23 |
| Resistance Level | $24.85 | $1.54 |
| Average True Range (ATR) | 0.79 | 0.16 |
| MACD | -0.17 | 0.00 |
| Stochastic Oscillator | 24.68 | 35.36 |
Price Performance
Historical ComparisonAbout INBK First Internet Bancorp
First Internet Bancorp is a bank holding company. Through its subsidiaries, it provides commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking or treasury management services. The company offers its products and services through the internet and does not have any branches. With operations organized into a single segment called the Commercial Banking segment, it also provides retail banking services.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.